Novartis, a Swiss drugmaker company, completed the acquisition of Arctos Medical, a company that specializes in gene therapy. Financial terms were not disclosed. “Optogenetics is emerging as a promising therapeutic approach that might restore sight to patients who are legally blind,” Jay Bradner, Novartis President.